新奥

Company News

Company News

【Invested enterprise】Diannei Biotech Source: Release time:2017-12-11 16:20:44 Back
\

         2017 China (Shanghai) Big Data Industry Innovation Summit was held on November 30, 2017 and December 1, 2017. General Manager Ge Liang of Diannei Biotech invested by NNFE was invited to attend the Summit; he had the speech of “Smart Healthcare” and participated in the round table theme forum as guest.

\

          In 2017 China Big Data Artificial Intelligence Innovation and Entrepreneurship Competition (Shanghai) Awards Ceremony in the Summit, four outstanding teams won the champion cups of technical and entrepreneurship competitions in the medical and financial field respectively. After brilliant showdown and rigorous assessment, Diannei Biotech got the AI entrepreneurship champion in Smart Healthcare.

          Public data shows that the artificial intelligence + medical market has reached 9.661 billion Yuan and increased 37.9% in China in 2016, it is expected to exceed 13 billion Yuan and increase 40.7% in 2017, and it is expected that the market size reaches 20 billion Yuan in 2018.

\
          GE Liang said in his keynote speech: Diannei (Shanghai) Biotechnology Co., Ltd. uses big data and artificial intelligence technology, combines with the application conditions of top hospitals in China, matches up the government departments, screens lung cancer early by artificial intelligence in the community,and helps people find and prevent early tumors.

          Ge Liang also said in his speech that through the automatic recognition and in-depth study of medical images as well as verification by the gold standard of pathology report further, the artificial intelligence technology can get lung cancer prediction earlier in just three minutes, and the accuracy reaches more than 80% which is close to the level of experts.

          As an annual event in the big data artificial intelligence filed, the Summit aims to find the outstanding talents and projects in big data and artificial intelligence, and build an important platform for cross-border collaboration for talent exchange, technological innovation, scene docking and application incubation, find the outstanding talents and projects for artificial enterprises , help industrial transformation and upgrading, and promote the innovation and development of the national big data artificial intelligence technology in the medical and financial fields further.
< Prev:The 17th China Capital and Equity Investment Annual Forum  Next:【Invested enterprise】 Elens Data>

Kindly Reminder

Continue to visit the company's website, please confirm you or your representative institutions for qualified investors in accordance with the provisions of the Securities Regulatory Commission China Private Securities Investment Fund (i.e. have the appropriate risk identification ability and the ability to bear the risk, investment in the private equity fund in the amount of not less than 1 million yuan, individual investors and financial assets not less than 3 million yuan or the last three years the average annual personal income is not less than 500 thousand yuan, net assets of institutional investors is not less than 10 million yuan, or other qualified investors recognized as regulators). The aforementioned "financial assets" include bank deposits, stocks, bonds, fund shares, asset management plans, financial products, trust plans, insurance products, futures interests, etc..
       If you enter, visit or use any of the pages of this website or any of these sites, you are deemed to be a "qualified investor" and are deemed to have accepted the terms and conditions of this website.
       The information, tools and materials presented on this website are for general reference only. Unless otherwise expressly agreed, does not constitute an advertisement or distribution, sales offer, or solicitation to buy any fund or any other investment products offer or offer invitation.
       Investment involves risk, investment product performance in the past does not indicate or imply its future performance, investors should read the product contract carefully before making investment decision, to seek appropriate professional investment and tax advice. Investors should not rely on the information provided by this website to make investment decisions.

If you or your representative institutions for qualified investors in accordance with the provisions of the Securities Regulatory Commission China private securities investment fund, and shall comply with the relevant laws and regulations applicable please click on Confirm "button to continue browsing our website. If you do not agree to any of the terms, please click " Give up " key.